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IMPORTANCE—Preclinical models and studies in the metastatic and neoadjuvant settings 
suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with 
differential response to trastuzumab in the treatment of ERBB2/HER2–positive breast cancer, by 
modulating antibody-dependent cell-mediated cytotoxic effects.
OBJECTIVE—To evaluate the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab 
efficacy in the adjuvant treatment of ERBB2/HER2–positive breast cancer.
DESIGN, SETTING, AND PARTICIPANTS—This is a retrospective analysis of patients 
enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial, a phase 
3 cooperative group study conducted between 2000 and 2005. The NSABP B-31 trial randomized 
2119 women with surgically resected node-positive, ERBB2/HER2–positive breast cancer to 
treatment with doxorubicin and cyclophosphamide followed by paclitaxel or the same regimen 
with the addition of 1 year of weekly trastuzumab. Patients were accrued at cooperative group sites 
across the United States and Canada. This analysis was performed between 2013 and 2016.
INTERVENTIONS—Doxorubicin and cyclophosphamide followed by paclitaxel or the same 
regimen with the addition of 1 year of weekly trastuzumab.
MAIN OUTCOMES AND MEASURES—Disease-free survival.
RESULTS—The genotyped cohort (N = 1251) resembled the entire B-31 cohort based on clinical 
variables and the degree of benefit from trastuzumab. Median follow-up time was 8.2 years in the 
genotyped samples. The disease-free survival probability at 3, 5, and 8 years was 74% (95%CI, 
71%–79%), 66%(95%CI, 62%–71%), and 58%(95%CI, 54%–63%) in patients who received ACT 
and 86%(95%CI, 83%–89%), 82%(95%CI, 79%–85%), and 78%(95%CI, 74%–81%) in patients 
who received ACTH. Addition of trastuzumab significantly improved patient outcome (hazard 
ratio [HR], 0.46; 95%CI, 0.37–0.57; P < .001). The expected trend for interaction between 
polymorphisms and trastuzumab was observed for both genes, but only FCGR3A-158 
polymorphism reached statistical significance for interaction (P < .001). As hypothesized, patients 
with genotypes FCB3A-158V/V or FCB3A-158V/F received greater benefit from trastuzumab 
(HR, 0.31; 95%CI, 0.22–0.43; P < .001) than patients who were homozygous for the low-affinity 
allele (HR, 0.71; 95%CI, 0.51–1.01; P = .05).
CONCLUSIONS AND RELEVANCE—The FCGR3A-158 polymorphism is predictive of 
trastuzumab efficacy in this cohort of patients with early ERBB2/HER2–positive breast cancer. 
Patients who are homozygous for phenylalanine at this position represent a considerable 
proportion of the population and, in contrast to previously reported analyses from similarly 
designed trials, our results indicate that trastuzumab may be less efficacious in these patients.
TRIAL REGISTRATION—clinicaltrials.gov Identifier for NSABP B-31: NCT00004067
Clinical trial National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31, analyzed 
jointly with the North Central Cancer Treatment Group (NCCTG) N9831, established the 
benefit of adding trastuzumab, a monoclonal antibody targeting the ERBB2/HER2 protein, 
to standard chemotherapy in patients with early stage ERBB2/HER2–positive breast cancer. 
However, only about one-third to one-half of patients benefit from this therapy in advanced 
or adjuvant settings, respectively.1,2 Although treatment is generally well tolerated, its high 
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cost, associated cardiotoxic effects, and the availability of promising alternatives warrant an 
attempt to identify patients who will not benefit.
Although many mechanisms have been attributed to the success of trastuzumab, the original 
patent described 2 primary potential mechanisms. First, by binding to ERBB2/HER2 on the 
cancer cell membrane, it prevents ERBB2/HER2 dimerization, blocks downstream 
signaling, and subsequently blocks proliferation. Second, it triggers the host immune system 
to attack and kill trastuzumab-bound tumor cells. This immune response, known as 
antibody-dependent cell-mediated cytotoxic effect (ADCC), is initiated when the FCγ 
receptor on natural killer cells (NK) binds to the Fc portion of trastuzumab. As a result, NK 
cells release factors including IFN-γ, perforins, and granzymes, which cause tumor cell 
death via apoptosis. A similar process, known as antibody-dependent cellular phagocytosis 
(ADCP), is initiated when the FCγ receptor on a macrophage binds to trastuzumab and 
results in tumor cell death by phagocytosis.
Early studies in ERBB2/HER2–positive breast cancer cell lines demonstrated potent ADCC 
caused by trastuzumab in vitro.3 Experiments in mice have demonstrated reduced 
trastuzumab efficacy if the Fc fragment is removed from the antibody or if the mouse is 
deficient in FCγ receptors.4,5 In addition, an increase in the infiltration of lymphoid cells 
into tumor samples was observed after trastuzumab treatment compared with paired 
pretreatment samples.6 Collectively, these findings support a strong role of ADCC or ADCP 
in the mechanism of trastuzumab efficacy.
Additional preclinical studies have demonstrated an association of single-nucleotide 
polymorphisms in the genes encoding FCγ receptors with the strength of the immune 
response. Many studies have focused on position 158 of FCGR3A, which encodes a valine 
or phenylalanine, and position 131 of FCGR2A, which encodes a histidine or arginine 
(reviewed in Mellor et al).7 In vitro ADCC assays demonstrated greater trastuzumab-
mediated ADCC with the FCGR3A-158 valine (V)/V genotype and a trend for association 
with the FCGR2A-131 histadine (H)/H genotype.8 Analyses of paired pretreatment and 
posttreatment peripheral blood mononuclear cells (PBMCs) demonstrated more differential 
changes in gene expression from patients with the V/V or H/H genotypes than did patients 
with phenylalanine (F)/F or arginine (R)/R genotypes, indicating a difference in the 
molecular response to trastuzumab according to genotype.9 These observations are 
consistent with the observation that the FCγRIIA-131H and FCγRIIIA-158V have a higher 
affinity to immunoglobin (IgG) than the proteins encoded by alternate alleles.10 Cells 
bearing the high-affinity alleles mediate ADCC more effectively.7
Clinical studies using therapeutic monoclonal antibodies such as rituximab for the treatment 
of lymphoma and cetuximab for the treatment of colon cancer have shown association of the 
FCGR3A and FCGR2A genotypes with patient outcomes.11–15 However, clinical studies 
examining the association of these single-nucleotide polymorphisms with trastuzumab 
benefit for patients with breast cancer are not clear. Tamura and colleagues16 demonstrated 
improved response rates to trastuzumab in patients with a FCGR2A-131 H/H genotype in 
the neoadjuvant setting and improved objective response rate in the metastatic setting. 
Musolino and colleagues8 observed improved objective response rate and progression-free 
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survival for patients with the FCGR3A-158 V/V genotype.8 However, while conducting our 
study, 2 large studies of patients enrolled in the NCCTG-N983117 and BCIRG-00618 clinical 
trials found no association of these loci with trastuzumab efficacy in the adjuvant treatment 
of ERBB2/HER2–positive breast cancer.
To explore this discrepancy, we retrospectively examined the FCGR3A-158 and 
FCGR2A-131 genotypes in all available pretreatment blood specimens from NSABPB-31. 
Our prespecified primary objective was to determine whether patients with breast cancer 
with FCGR3A-158 V/V or FCGR3A 158 V/F received greater benefit from trastuzumab 
than patients with the FCGR3A F/F genotype.
Methods
Patient Cohort
Detailed patient characteristics, eligibility criteria, adverse events, and clinical trial results 
have previously been reported.2,19,20 The NSABPB-31 trial randomly assigned women with 
surgically resected node-positive ERBB2/HER2–positive breast cancer to treatment with 
doxorubicin and cyclophosphamide followed by paclitaxel (ACT) or the same regimen with 
the addition of 1 year of weekly trastuzumab (ACTH). Patients were accrued between 
February 2000 and April 2005 at cooperative group sites across the United States and 
Canada. Treatment assignments were balanced according to nodal status, planned hormonal 
therapy, type of surgery, intended radiotherapy, and institution, with the use of a biased-coin 
minimization algorithm. Additional inclusion requirements for the current study include 
availability of clinical follow-up, appropriate informed consent, and availability of 
pretreatment blood specimens. Informed consent forms were approved by a local human 
investigations committee in accordance with an assurance filed with and approved by the US 
Department of Health and Human Services to permit use of banked tissue and blood 
samples. These trials were approved by local human investigations committees or 
institutional review boards in accordance with assurances filed with and approved by the 
Department of Health and Human Services. Written informed consent was obtained from 
participants in each trial.
Genotyping
Whole blood was collected before treatment and stored at −80° C. Participant DNA was 
prepared from 100 μL of whole blood using the Mag-Bind Blood DNA HDQ kit (Omega 
Biotek) and quantified with picogreen (ThermoFisher). Genotyping of rs1801274 
(FCGR2A-131 R/H) and rs396991 (FCGR3A-158 V/F) was performed using iPLEX Pro 
chemistry and mass spectrometry (Agena) according to the manufacturer’s instructions. 
Nested polymerase chain reaction was used for FCGR3A-158 to achieve specificity against 
its homologue FCGR3B. Genotypes were determined with Typer software using default 
settings after autoclustering (Agena). Two-thirds of the rs396991 assays were performed in 
duplicate. Bacterial artificial chromosome clones RP11-5K23 (FCGR3A), RP11-100D4 
(FCGR3B), and an equimolar mixture of the 2 were used as controls to ensure the rs396991 
primers specifically amplified the 3A homologue. Detailed reaction conditions and primer 
Gavin et al. Page 4













sequences are provided in eMethods in the Supplement. All assays were performed blinded 
to clinical outcome using deidentified specimens.
Statistical Methods
The use of patient blood specimens and a detailed statistical analysis plan were approved by 
the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) 
before starting the current investigation. The primary end point for survival analyses was 
disease-free survival. Disease-free survival events included local, regional, and distant 
recurrence; contralateral breast cancer; a second primary cancer; or death from any cause. 
Follow-up included events recorded before June 30, 2012. In 2005, during a planned joint 
analysis with NCCTG-N9831, the early-stopping boundary was reached and patients on the 
ACT arm were offered trastuzumab. Patients who crossed over to the trastuzumab arm were 
censored at the time of crossover. The treatment benefit and prognostic effect for each 
genotype was first investigated using the Kaplan-Meier method and treatment arms were 
compared using log-rank tests. As the primary aim, FCGR3A genotype by treatment 
interaction was tested using proportional hazard regression models. For purposes of the 
interaction tests, the high-affinity genotypes were combined (FCGR3A-158 V/V or V/F vs. 
F/F). Similar analyses were performed for FCGR2A as a secondary objective. Survival 
analyses provided here were adjusted for estrogen receptor (ER) (positive or negative), 
progesterone receptor (PR) (positive or negative), age (years), tumor size (cm), and nodal 
status (1–3, 4–9, or ≥10 positive lymph nodes). Univariable models are reported in the 
Supplement or are clearly indicated as such. Missing values in the covariates resulted in the 
exclusion of 8 cases for multivariable analyses of FCGR3A and 7 cases for FCGR2A. The 
Fisher exact test was used to test deviation from Hardy Weinberg Equilibrium and to test the 
association of genotype with clinical characteristics. Linkage disequilibrium was 
investigated in the subset of patients with results for both assays. All statistical tests were 2-
sided and performed in R.
Results
Patient Characteristics
Among 2006 eligible patients with follow-up and informed consent, pretreatment blood 
specimens were available for 1253 and DNA was successfully prepared for 1251. Details 
regarding the reasons for sample loss are shown in eFigure 1 in the Supplement. Clinical and 
pathological characteristics were well balanced in the treatment arms of the study population 
and closely resembled the entire B-31 cohort (eTable 1 and eTable 2 in the Supplement). 
Median follow-up time was 8.2 years in the genotyped samples. The disease-free survival 
probability at 3, 5, and 8 years was 74%(95%CI, 71%–79%), 66%(95%CI, 62%–71%), and 
58% (95% CI, 54%–63%) in patients who received ACT and 86% (95% CI, 83%–89%), 
82% (95% CI, 79%–85%), and 78% (95% CI, 74%–81%) in patients who received ACTH. 
Addition of trastuzumab significantly improved patient outcome (hazard ratio [HR], 0.46; 
95% CI, 0.37–0.57; P < .001).
Gavin et al. Page 5














Of 883 assays performed in duplicate, 3 discordances were observed (0.3%) for 
FCGR3A-158 (rs396991). These 3 observations were excluded from further analysis. 
Approximately 2% of FCGR2A-131 and 7% of FCGR3A-158 assays failed default 
genotyping quality controls in the Typer software, yielding 21 and 87 missing values, 
respectively. Some of the FCGR3A reactions excluded by the software may actually 
represent heterozygous patients with 3 germline copies of the gene.21 However, these wells 
are indistinguishable from wells with contamination or poor reaction conditions and their 
expected frequency of 2.5%limits our power to detect meaningful clinical significance. For 
these reasons, any sample that failed quality control was eliminated. Thirteen samples failed 
both assays, suggesting poor-quality DNA. The patients genotyped showed 25% H/H, 49% 
H/R, and 26% R/R alleles for FCGR2A-131 and 46%F/F, 42% F/V, and 12% V/V for 
FCGR3A-158. Both loci conform to the Hardy Weinberg Equilibrium in our data. In 1156 
specimens with both assays successful, linkage disequilibrium analysis indicated the 
FCGR3A and FCGR2A genes are strongly linked (D′ = 0.30; P < .001) as expected from 
their close genomic proximity and previous studies.18
FCGR Polymorphisms and Clinical Characteristics
FCGR3A-158 single-nucleotide polymorphisms were not associated with nodal status, ER, 
PR, tumor size, or race (eTable 3 in the Supplement). However, patients with the 
homozygous V/V genotype tended to be older (P < .001). The mean age was 52 years for 
V/V patients and 49 to 50 years for the other genotypes. FCGR2A-131 was not associated 
with nodal status, ER, PR, tumor size, or age. However, it was weakly associated with race 
(eTable 4 in the Supplement).
FCGR3A Polymorphism and Trastuzumab Efficacy
Patients with genotypes that included the higher-affinity alleles FCGR3A-158 V/V or V/F 
received greater benefit from trastuzumab (HR, 0.31; 95% CI, 0.22–0.43; P < .001) than 
patients who were homozygous for the low-affinity allele (HR,0.71; 95% CI,0.51–1.01; P = .
05) (Figure 1A and B). Genotype by treatment-interaction test indicates an association 
between FCGR3A-158 and benefit from trastuzumab (P < .001). In an exploratory analysis, 
the FCGR3A-158, high-affinity V/V homozygous patients received the most benefit (HR, 
0.12; 95% CI, 0.05–0.28; P < .001), heterozygous F/V patients received intermediate benefit 
(HR, 0.34; 95%CI, 0.23–0.48; P < .001), and homozygous low-affinity F/F patients received 
the least benefit (HR, 0.71; 95% CI, 0.51–1.01; P = .05) (Figure 2). Similar results were 
observed using invariable models.
FCGR2A Polymorphism and Trastuzumab Efficacy
The FCGR2A polymorphism demonstrated the trends expected from preclinical models 
(Figure 2). FCGR2A-131, high-affinity H/H homozygous patients received the most benefit 
(HR, 0.31; 95%CI, 0.19–0.49; P < .001), heterozygous H/R patients received intermediate 
benefit (HR, 0.50; 95% CI, 0.37–0.68; P < .001), and homozygous low-affinity R/R patients 
received the least benefit (HR, 0.57; 95%CI, 0.35–0.92; P = .02) (Figure 2). However, 
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treatment interaction tests indicate no difference in trastuzumab efficacy according to 
FCGR2A-131 (P = .24 for H/H or H/R vs. R/R).
FCGR Polymorphism and Prognosis
In an exploratory analysis in the ACT arm, patients with FCGR3A-158 V/For V/V had 
worse prognosis than patients with F/F (HR, 1.57; 95% CI, 1.15–2.14; P = .005) (eFigure 2 
in the Supplement). On the other hand, in the ACTH arm, patients with FCGR3A-158 V/F 
or V/V had better prognosis than patients with F/F (HR, 0.68; 95% CI, 0.48–0.96; P = .03). 
Univariable models demonstrated similar results. FCGR2A-131 genotypes showed no 
evidence of prognosis in either arm.
Combined Genotypes
Additional exploratory analyses revealed approximately 15%of the population are 
homozygous for both of the low-affinity alleles (FCGR3A-158 F/F and FCGR2A-131 R/R; 
n = 179) (Figure 3). Trastuzumab appears less effective in these patients (HR,0.81; 95%CI,
0.41–1.58; P = .53). However, treatment interaction tests of this population were not 
significant (P = .06 for F/F and R/R vs others).
Discussion
Analysis of FCGR3A-158 polymorphism in NSABP B-31 demonstrated differential 
trastuzumab benefit predicted by preclinical models, studies of other antibodies, and smaller 
studies of trastuzumab in the metastatic and neoadjuvant settings.7 Treatment interaction 
tests indicate polymorphisms at this position are associated with variability in the degree of 
benefit from adjuvant trastuzumab. Patients with the 158 F/F genotype have a better 
prognosis when treated with ACT and received less relative benefit (HR, 0.71) from the 
addition of trastuzumab, where as patients with 158 F/V or V/V have a worse prognosis with 
ACT and receive significantly more relative benefit from trastuzumab (HR, 0.31). These 
results indicate that ADCC may play a substantial component in the efficacy of trastuzumab 
for the treatment of breast cancer in the adjuvant setting; ADCC also activates tumor–
antigen-specific cellular immunity via intercellular crosstalk among NK and dendritic cells, 
which may also enhance the efficacy of anti-ERBB2/HER2 therapy.22,23
We also observed that the FCGR2A-131 polymorphism showed the expected trend for 
trastuzumab benefit but treatment interaction tests indicated no evidence of differential 
trastuzumab treatment effect according to FCGR2A genotypes. Perhaps this may be owing 
to the lack of expression of FCγRIIa on NK cells because NK cells are thought to be the 
main effectors of ADCC; although cytotoxic effects mediated through other effector cells via 
FCγRIIa have been reported.24 Our observation that the significant differential benefit from 
trastuzumab was limited to the FCGR3A-158 polymorphism and was not seen in the 
FCGR2A-131 single-nucleotide polymorphisms may also be owing to the fact that 
FCγRIIIa-158V was found to bind to IgG1 immune complexes at low concentrations but did 
not bind to FCγRIIIa-158F. Conversely, no binding differences were detected between 
FCγRIIa-131H and 131R at low IgG1 concentrations.25
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Our results differ from recent reports from the NCCTG-N983117 and BCIRG-006 trials,18 
which found no association of FCGR3A-V158 and benefit from trastuzumab. These trials 
also examined the addition of trastuzumab to ACT in the adjuvant treatment of ERBB2/
HER2–positive breast cancer and differed from NSABP B-31 primarily in the timing of the 
treatments. Both studies had sample sizes remarkably similar to our own and demonstrated 
substantial benefits from the addition of trastuzumab to chemotherapy. The methodologies 
used were rigorous: BCIRG-006 measured each single-nucleotide polymorphisms in 
quadruplicate (duplicate measurements on 2 platforms) and NCCTG-N9831 had 100% 
concordance in one-third of the population measured in duplicate. However, both of the 
previous FCGR studies suffered from sampling bias. In the BCIRG-006 study, the 1286 
patients who were genotyped did not show significant benefit from trastuzumab (HR, 0.84; P 
= .19) and the authors acknowledged that they cannot exclude a contribution of FCGR 
polymorphisms to the outcome of trastuzumab-treated patients due to the sampling bias. 
FCGR3A-158 also deviated from the Hardy Weinberg Equilibrium in the BCIRG-006 study. 
Blood for genotyping was collected from NCCTG-N9831 patients after the trial closed to 
accrual, leading to differences from the study population and the intent-to-treat population. 
The NCCTG-N9831–genotyped cohort included a greater proportion of trastuzumab-treated 
patients, less nodal disease, smaller tumors, a greater number of hormone receptor–positive 
tumors, and patients who were slightly older than the entire NCCTG-N9831 cohort. As a 
result, the genotyped patients had a substantially better disease-free survival than the entire 
NCCTG-N9831 cohort. For both studies, these biases resulted in a loss of events and as a 
result reduced power to detect genotype-treatment interaction.
In our exploratory analysis, the observation that the FCGR3A low-affinity allele was 
associated with a better prognosis than the high-affinity allele in the ACT arm was 
unexpected. Chemotherapy has been shown to induce an immune response and possibly the 
differential binding affinity of FCγRIIIa-158V and FCγRIIIa-158F proteins to intrinsic 
antibodies may result in differential benefit from chemotherapy. Polymorphisms in other 
immune molecules such as TLR426 and P2RX727 have been reported as candidate 
biomarkers predicting progression-free survival associated with chemotherapy-elicited cell 
death in breast cancer. The observed direction for prognosis is in the opposite direction that 
might be expected based on the binding affinities of the 2 alleles and might represent a 
chance finding. However, the considerably diverse expression of this receptor on a number 
of different immune cells (macrophages, γΔT cells, and many others) taken together with a 
wide variety of functions that often vary depending on the local microenvironment suggests 
that clinical outcomes can be very difficult to predict.
We have shown that patients with breast cancer with 1 or 2 of the FCGR3A-158V alleles 
receive greater benefit from trastuzumab than patients who are homozygous for the 
FCGR3A-158F allele. Although multivariable analysis showed that patients with the F/F 
genotype had a slightly higher residual risk, this difference was not remarkable. Thus, 
genotyping does not seem to be sufficient for selection of patients for additional treatment.
Currently, many therapies, including new anti-ERBB2/HER2 monoclonal antibodies or pan-
tyrosine kinase inhibitors are being used in addition to trastuzumab to treat patients with 
breast cancer in the metastatic and neoadjuvant settings. These agents also engage the 
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immune system and boost trastuzumab-induced ADCC.28–30 Recent investigation of 
additional immune checkpoint inhibitors to anti-ERBB2/HER2 therapies in patients with 
ERBB2/HER2–positive metastatic breast cancer is based on the hypothesis that a substantial 
component of trastuzumab benefit is mediated through ADCC and cross-priming of antigen-
specific cytotoxic T cells,22,23,31 which could enable the inhibition of immune checkpoints 
to improve the long-term efficacy of anti-ERBB2/HER2 therapy. However, carefully 
designed clinical trials would be needed to determine if additional agents enhance 
trastuzumab activity in specific genotypes.
Studies on NK cell mediated therapies suggest that the Fc region on monoclonal antibodies 
such as trastuzumab could be re-engineered to augment the affinity for a variety of inhibitory 
and activating FCGR allelotypes.10,32,33 Single amino acid changes to the antibody at the 
binding site can strongly influence the binding strength. This notion also requires additional 
clinical studies.
Conclusions
This study supports the hypothesis that ADCC activity plays an important role in the 
efficacy of trastuzumab. However, a great number of different molecules are involved in 
determining ADCC activity, therefore it may be useful to collect peripheral blood monocytes 
from patients in future clinical trials so that functional ADCC activity can be assessed and 
associated with treatment efficacy of trastuzumab and other therapeutic monoclonal 
antibodies.34
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Do polymorphisms in FCγ receptors affect trastuzumab efficacy?
Findings
In this secondary analysis of 1251 patients with early-stage ERBB2/HER2–positive 
breast cancer enrolled in a randomized clinical trial, patients homozygous for 
FCGR3A-158 F benefited less from the addition of trastuzumab to chemotherapy than 
did patients with F/V or V/V genotypes.
Meaning
Significant association between polymorphisms of FCGR3A and trastuzumab benefit 
suggests that antibody-dependent cell-mediated cytotoxic effect plays a role in 
determining the efficacy of trastuzumab in the adjuvant treatment of ERBB2/HER2–
positive breast cancer.
Gavin et al. Page 12













Figure 1. Treatment Effect According to FCGR Polymorphism
ACT indicates doxorubicin and cyclophosphamide followed by paclitaxel; ACTH, 
doxorubicin and cyclophosphamide followed by paclitaxel with the addition of 1 year of 
weekly trastuzumab; DFS, disease-free survival; HR, hazard ratio; M, multivariable; U, 
univariable.
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Figure 2. Cox Models Examining Treatment Affect According to Genotype
The box size is proportional to the precision. ACTH, doxorubicin and cyclophosphamide 
followed by paclitaxel with the addition of 1 year of weekly trastuzumab; HR, hazard ratio.
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Figure 3. Combined Genotypes
ACT indicates doxorubicin and cyclophosphamide followed by paclitaxel; ACTH, 
doxorubicin and cyclophosphamide followed by paclitaxel with the addition of 1 year of 
weekly trastuzumab; DFS, disease-free survival; HR, hazard ratio; M, multivariable; U, 
univariable.
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